Trial record 1 of 1 for:    NCT00687934
Previous Study | Return to List | Next Study

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
Synta Pharmaceuticals Corp.
ClinicalTrials.gov Identifier:
NCT00687934
First received: May 28, 2008
Last updated: January 30, 2014
Last verified: January 2014
  Purpose

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)


Condition Intervention Phase
Solid Tumors
Drug: STA-9090
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Resource links provided by NLM:


Further study details as provided by Synta Pharmaceuticals Corp.:

Primary Outcome Measures:
  • The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities [ Time Frame: Cycle 1 ] [ Designated as safety issue: Yes ]

Enrollment: 53
Study Start Date: October 2007
Study Completion Date: October 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: STA-9090
    This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
  Eligibility

Ages Eligible for Study:   25 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be documented to be refractory or not candidates for current approved therapies.
  • Must have an ECOG status 0-2.
  • Peripheral neuropathy < or = 2.
  • Must have acceptable organ and marrow function per protocol parameters.
  • No clinically significant ventricular arrythmias or ischemia.

Exclusion Criteria:

  • Must not be pregnant or breastfeeding.
  • Chemotherapy or radiation within 3 weeks.
  • Previous radiation to >25% of total bone marrow.
  • Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation.
  • Primary brain tumors or active brain metastases.
  • Use of any investigational agents within 4 weeks.
  • Treatment with chronic immunosuppressants.
  • Uncontrolled, intercurrent illness.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00687934

Locations
United States, California
Premiere Oncology
Santa Monica, California, United States, 90404-2111
United States, Ohio
US Oncology Dayton Oncology and Hematology, P.A
Kettering, Ohio, United States, 45409
Sponsors and Collaborators
Synta Pharmaceuticals Corp.
  More Information

No publications provided by Synta Pharmaceuticals Corp.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Robert Bradley/Clinical Trial Manager, Synta Pharmaceuticals Corp.
ClinicalTrials.gov Identifier: NCT00687934     History of Changes
Other Study ID Numbers: 9090-02, 9090-02
Study First Received: May 28, 2008
Last Updated: January 30, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Synta Pharmaceuticals Corp.:
metastatic cancer
solid tumor
histologically or cytologically confirmed non-hematological
malignancy that is metastatic or unresectable for which no
standard therapy exists
STA-9090
ganetespib

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on April 16, 2014